The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.
In a three-year follow-up study, fewer than 2% of long COVID cases reported resolution of symptoms, with vaccinated patients demonstrating significantly better physical and mental health outcomes.
A new study found that 6.4% of patients with hidradenitis suppurativa were hospitalized for serious infections not related to their skin condition, with the highest risk seen in those with chronic kidney disease, anxiety, and public insurance.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.